Clinical Trials Browser

Colorectal Neoplasms

Platinum-Refractory Fallopian Tube Carcinoma

Lymphoma, Non-Hodgkin

Carcinoma, Merkel Cell

Carcinoma, Non-Small-Cell Lung

Colorectal Neoplasms

Carcinoma, Transitional Cell

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

Carcinoma, Non-Small-Cell Lung

C04.588.274.476.411.307

Liver Neoplasms, Cholangiocarcinoma

Breast Neoplasms, Lung Neoplasms, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms

Carcinoma, Hepatocellular

Glioblastoma

Colorectal Neoplasms

Ovarian Neoplasms

Colorectal Neoplasms

Glioblastoma, Glioma

Glioblastoma

Endometrial Neoplasms

Carcinoma, Renal Cell

Peritoneal Neoplasms

Rectal Cancer Patients

Colorectal Neoplasms

Colonic Neoplasms, Colorectal Neoplasms

Glioblastoma

Glioblastoma, Recurrence

Uterine Cervical Neoplasms

Colonic Neoplasms, Neoplasm Metastasis, Rectal Neoplasms, Colorectal Neoplasms

Ovarian Neoplasms

Colorectal Neoplasms

Colonic Neoplasms, Rectal Neoplasms

Central Nervous System Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Colorectal Neoplasms

Carcinoma, Renal Cell

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Brain Neoplasms, Melanoma

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Neoplasms, Small Cell Lung Carcinoma

Colonic Neoplasms, Colorectal Neoplasms

Neoplasms, Unknown Primary

Adrenocortical Carcinoma

Head and Neck Neoplasms

Esophageal Neoplasms

Carcinoma, Non-Small-Cell Lung

Colorectal Neoplasms

Clinical Trials

INAVO-CRC

Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer

QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL

QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy

QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy

QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors

QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC

QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

SMMART Adaptive Clinical Treatment (ACT) Trial

A Phase I/II Study of AMG 510 in Combination With MVASI in Patients With Advanced, Unresectable or Metastatic KRAS G12C Mutant NSCLC With Asymptomatic Brain Metastasis

CPI-613 (Devimistat) in Combination With Modified FOLFIRINOX Plus Bevacizumab in Patients With Metastatic Colorectal Cancer

Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/Amplification

Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors

Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T

Golden Halo, Static Magnetic and Electric Field Device, in Recurrent Glioblastoma

Pemetrexed and S-1 in Combination With Bevacizumab in Refractory Colorectal Cancer

Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian Cancer

SIRB2

A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma

Surgery With Implantable Biodegradable Carmustine (BCNU) Wafer Followed by Chemo for Patients With Recurrent Glioblastoma Multiforme

Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer

A Study of Atezolizumab in Combination With Bevacizumab in Untreated Locally Advanced or Metastatic Clear Cell or Non-Clear Cell Renal Cell Carcinoma

Perioperative Chemotherapy With Bevacizumab for Colorectal Carcinomatosis French Part of the Main Bev-IP Study

DCE-MRI PET Bevacizumab Study in Rectal Cancer

A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Previously Untreated Metastatic Colorectal Cancer.

A New Agent GM-CT-01 in Combination With 5-FU, Avastin and Leucovorin in Subjects With Colorectal Cancer

Preliminary Assessment of [18F] Fluciclatide (GE [18F]AH111585) in Glioblastoma Multiforme Treated With Bevacizumab

Ph II Cilengitide Plus Bevacizumab for Recurrent Glioblastoma (GBM)

Neoadjuvant Bevacizumab and Carboplatin Followed by Concurrent Bevacizumab, Carboplatin and Radiotherapy in the Primary Treatment of Cervix Cancer

Oxaliplatin, Capecitabine, and Bevacizumab Followed By Surgery and/or Radiofrequency Ablation in Patients With Colorectal Cancer

DCVax-L Vaccination With CD3/CD28 Costimulated Autologous T-Cells for Recurrent Ovarian or Primary Peritoneal Cancer

PRIMIER

Combination Chemotherapy and Bevacizumab With or Without RO4929097 in Treating Patients With Metastatic Colorectal Cancer

OXC401-PO1s/WVU 1309 - A Pilot Study of Fosbretabulin With Bevacizumab in Recurrent High-Grade Gliomas

PRIMADOS Study:A Study of Avastin (Bevacizumab) Plus Docetaxel for First Line Treatment of Patients With Metastatic Breast Cancer

A Study of Herceptin (Trastuzumab) in Combination With Avastin (Bevacizumab) and Sequential Xeloda (Capecitabine) or Docetaxel in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer

A Study of The Safety Profile of First-line Avastin (Bevacizumab) in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Her2-negative Breast Cancer (AVATAX)

A Study of Avastin (Bevacizumab) in Combination With mFOLFOX6 in Treatment-Naïve Patients With Metastatic Colorectal Cancer With or Without K-RAS Mutations, and Comparison to Cetuximab

Efficacy and Safety Study of rhuMAb VEGF to Treat Metastatic Renal Cell Carcinoma

Cetuximab and Bevacizumab as First-Line Therapy Followed By Combination Chemotherapy and Bevacizumab With or Without Cetuximab as Second-Line Therapy in Treating Patients With Stage IV Colorectal Cancer

Combo of Abraxane, TMZ, Bevacizumab in Metastatic Melanoma With Brain Metastases

Enzastaurin, Carboplatin, and Gemcitabine With or Without Bevacizumab in Treating Patients With Recurrent, Stage IIIB, or Stage IV Non-Small Cell Lung Cancer

Metronomic Docetaxel and Bevacizumab in Patients With Small Cell Lung Cancer

FAST

Cisplatin/Paclitaxel/Gemcitabine +/- Avastin in Patients With Unknown Primary Tumor

Treatment Study Using Bevacizumab for Patients With Adrenocortical Carcinoma

Pilot Study for Locally Advanced Head and Neck Cancer

Study of Cetuximab and Bevacizumab in Cancer of the Esophagus After Failure of Patient's First Therapy

SELECT-A

IXO+A in mCRC With Liver-only Metastases